Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $6.7 million.

  • Immunome's Share-based Compensation rose 37.92% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year increase of 76.79%. This contributed to the annual value of $15.7 million for FY2024, which is 153.06% up from last year.
  • Per Immunome's latest filing, its Share-based Compensation stood at $6.7 million for Q3 2025, which was up 26.18% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Share-based Compensation registered a high of $6.7 million during Q3 2025, and its lowest value of $1.0 million during Q2 2023.
  • In the last 3 years, Immunome's Share-based Compensation had a median value of $3.2 million in 2024 and averaged $3.6 million.
  • Data for Immunome's Share-based Compensation shows a peak YoY surged of 351.71% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunome's Share-based Compensation stood at $2.9 million in 2023, then surged by 89.73% to $5.5 million in 2024, then skyrocketed by 37.92% to $6.7 million in 2025.
  • Its Share-based Compensation was $6.7 million in Q3 2025, compared to $5.3 million in Q2 2025 and $5.7 million in Q1 2025.